Skip to main content

Mosunetuzumab Side Effects

Medically reviewed by Drugs.com. Last updated on Mar 19, 2024.

Applies to mosunetuzumab: intravenous solution.

Warning

Intravenous route (Solution)

Warning: Cytokine Release SyndromeCytokine release syndrome (CRS), including serious or life-threatening reactions, can occur in patients receiving mosunetuzumab-axgb. Initiate treatment with the mosunetuzumab-axgb step-up dosing schedule to reduce the risk of CRS. Withhold mosunetuzumab-axgb until CRS resolves or permanently discontinue based on severity.

Serious side effects of Mosunetuzumab

Along with its needed effects, mosunetuzumab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking mosunetuzumab:

More common

Incidence not known

Other side effects of Mosunetuzumab

Some side effects of mosunetuzumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to mosunetuzumab: intravenous solution.

General

-The most common adverse reactions with a frequency of 20% or greater were cytokine release syndrome , fatigue , rash , pyrexia , and headache.

-Adverse reactions that required dosage interruption in greater than or equal to 5% of patients included neutropenia, infection, and cytokine release syndrome.[Ref]

Dermatologic

Rash included rash erythematous, exfoliative rash, rash macular, rash maculo-papular, rash papular, rash pruritic, rash pustular, erythema, palmar erythema, dermatitis, and dermatitis acneiform.[Ref]

Very common (10% or more): Dry skin (16%), pruritus (21%), rash (39%)

Common (1% to 10%): Skin exfoliation[Ref]

Gastrointestinal

Very common (10% or more): Abdominal pain (12%), diarrhea (17%), nausea (17%)[Ref]

Abdominal pain included lower abdominal pain and abdominal discomfort.[Ref]

Genitourinary

Urinary tract infection included urinary tract infection and acute pyelonephritis.[Ref]

Common (1% to 10%): Urinary tract infection[Ref]

Hematologic

Very common (10% or more): Decreased lymphocyte count (100%), decreased hemoglobin (68%), decreased neutrophils (58%), decreased platelets (46%), decreased white blood cells (60%)[Ref]

Immunologic

Very common (10% or more): Cytokine release syndrome (44%)[Ref]

Metabolic

Very common (10% or more): Uric acid increased (22%)

Frequency not reported: Tumor lysis syndrome[Ref]

Musculoskeletal

Very common (10% or more): Arthralgia (11%), musculoskeletal pain (28%)[Ref]

Musculoskeletal pain included back pain, myalgia, musculoskeletal chest pain, and neck pain.[Ref]

Nervous system

Very common (10% or more): Dizziness (12%), headache (32%), peripheral neuropathy (20%)

Frequency not reported: Motor dysfunction[Ref]

Headache included headache and migraine. Peripheral neuropathy included peripheral sensory neuropathy, paresthesia, dysesthesia, hypoesthesia, burning sensation, and neuralgia. Dizziness included dizziness and vertigo. Motor dysfunction included ataxia, gait disturbance and tremor.[Ref]

Oncologic

Frequency not reported: Tumor flare

Other

Fatigue included asthenia, and lethargy. Edema included edema peripheral, peripheral swelling, face edema, swelling face, pulmonary edema, fluid overload, and fluid retention.[Ref]

Very common (10% or more): Chills (13%), decreased platelets (46%), decreased phosphate (78%), decreased magnesium (33%), edema (17%), fatigue (42%), increased glucose (42%), increased aspartate aminotransferase (39%), increased alanine aminotransferase (32%), increased gamma-glutamyl transferase (34), pyrexia (29%)

Frequency not reported: EBV viremia, sepsis[Ref]

Psychiatric

Very common (10% or more): Insomnia (12%)

Frequency not reported: Mental status changes, anxiety[Ref]

Renal

Frequency not reported: Renal insufficiency[Ref]

Respiratory

Very common (10% or more): Dyspnea (11%), cough (22%), upper respiratory tract infection (14%)

Frequency not reported: COVID-19, pneumonia[Ref]

Cough includes cough, productive cough, and upper airway cough syndrome. Dyspnea included dyspnea and dyspnea exertional. Upper respiratory tract infection includes upper respiratory tract infection, nasopharyngitis, sinusitis, and rhinovirus infection.[Ref]

References

1. Product Information. Lunsumio (mosunetuzumab). Genentech. 2022.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.